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Recent technological and protocol developments have greatly increased the ability to
utilize stem cells transformed into cardiomyocytes as models to study human heart
muscle development and how this is affected by disease associatedmutations in a variety
of sarcomere proteins. In this perspective we provide an overview of these emerging
technologies and how they are being used to create better models of “disease in a dish”
for both research and screening assays. We also consider the value of these assays as
models to explore the seminal processes in initiation of the disease development and the
possibility of early interventions.
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It has now been over 35 years since the first report of a genetic linkage between a sarcomere protein
mutation (or variant) with a disease phenotype (Geisterfer-Lowrance et al., 1990). Since then well
over 1000 genetic variants of sarcomere proteins have been reported as associated with diseases such
as hypertrophic, dilated, or restrictive cardiomyopathy, thoughmany fewer have been confirmed as
having causative roles (Seidman and Seidman, 2011; Haas et al., 2015). The vast majority of research
to understand the phenotypic consequences of these genetic variants has been done using post-
natal animals, cell culture, and recombinant protein models. Thus, much has been learned about
later stages of the disease process, likely after multiple compensatory processes have been invoked
and often when hearts are in failure. However, there is growing consensus that to find effective
treatments for these familial diseases it is important to understand the role of these mutations in
earlier stages in disease progression, before clinical signs manifest and perhaps at the earliest stages
of human development.
The development of technologies to derive human pluripotent stem cells and differentiate them
into cardiomyocytes has provided a model system in which to study these crucial early stages of
development. Beginning with the derivation of the first human embryonic stem cell line in 1998
(Thomson et al., 1998) and continuing with the derivation of human induced pluripotent stem cells
(hiPSCs) in 2007 (Takahashi and Yamanaka, 2006), it has been theoretically possible to generate
any tissue in the lab. However, early differentiation protocols for cardiomyocytes depended upon
the spontaneous formation of embryoid bodies and resulted in low yields of cardiomyocytes
(∼1–5%; Kehat et al., 2001). Better understanding of pathways involved in heart development
in vivo has since been leveraged to develop more efficient differentiation protocols and it is now
possible to achieve >90% pure cardiomyocyte populations using multiple methods (Spater et al.,
2014). Additionally, these technologies in reprogramming and directed differentiation have made it
possible to generate cell lines and large numbers of cardiomyocytes from patient samples and have
laid the foundation for hiPSC-based cardiac disease modeling.
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A series of technological advances in genomic engineering
have also advanced the ability to model cardiomyopathies with
hiPSC-derived cardiomyocytes (hiPSC-CMs). Until recently, cell
lines have largely been generated using samples from patients
who both (1) carry a known or suspected pathogenic mutation
and (2) clinically present with cardiomyopathy. A major benefit
of this approach is that the resulting cell line will carry both
the mutation of interest as well as any undefined or unknown
genetic modifiers that may be necessary for presentation of the
disease phenotype. This enhances the likelihood that a phenotype
will emerge in vitro. However, it can often be difficult to
establish appropriate controls for patient-derived cell lines. Even
control cell lines established from healthy close relatives can have
significant genetic variation compared to the cardiomyopathy
line, and when relatives’ samples are unavailable often completely
unrelated wildtype cell lines are used (Siu et al., 2012; Lin et al.,
2015). Nevertheless, this has been used to successfully study both
hypertrophic (Lan et al., 2013) and dilated (Sun et al., 2012; Wu
et al., 2015) cardiomyopathy and gain mechanistic insights into
the pathogenesis of these mutations.
Breakthroughs in genome engineering technologies, notably
the development of the CRISPR/Cas9 system for use in
mammalian systems, currently allow for the generation of
isogenic control lines in hiPSC-CM modeling. Using a 20-base
pair single guide RNA, the CRISPR/Cas9 system can create
double-stranded breaks at nearly any location in the genome.
This allows for the straightforward generation of random
mutations using non-homologous end joining (NHEJ), as well
as specific base pair changes at lower efficiencies by supplying a
template for homology-directed repair (HDR; Ran et al., 2013).
More recent advances have focused on improving the efficiency
of HDR (Chu et al., 2015; Yu et al., 2015) and increasing the target
range of CRISPR systems by mutating the commonly used Cas9
nuclease (Kleinstiver et al., 2015a) and deriving nucleases from
different species of bacteria (Kleinstiver et al., 2015b).
Two general approaches are available for using genome
engineering in hiPSC-CM modeling. In the first, mutations can
be specifically engineered into a healthy, wildtype hiPSC line.
A significant benefit to this approach is that many different
mutations can be tested on the same genetic background,
allowing for a rigorous comparison. Particularly for non-sense
mutations, this can be done in a relatively high-throughput
manner through the use of NHEJ. Alternatively, mutations in
a patient-derived line can be corrected using HDR. However,
this is often technically more problematic, and it can be
difficult to discern if performance returns to healthy, wildtype
levels. Although these genome engineering technologies are
still relatively new, it is clear that controls generated using
these techniques are more accurate than cell lines created from
unaffected relatives or unrelated individuals. In the future,
isogenic controls should be considered a standard in hiPSC-CM
disease modeling.
There are numerous technologies for phenotyping hiPSC-
CMs. Of particular interest in many cardiomyopathies are
mechanical function measurements of hiPSC-CMs, which can
be acquired on single cells or in the context of a multicellular
tissue engineered system. Current assays allow for highly
sensitive measurements of both force production and kinetics of
hiPSC-CM contraction and relaxation, and these measurements
have been successfully used to characterize the phenotype of
several hiPSC-CM cardiomyopathy models (Sun et al., 2012;
Hinson et al., 2015). Recent reviews provide comprehensive
coverage of both single cell measurement systems (Polacheck
and Chen, 2016) and multicellular tissue engineering approaches
(Tzatzalos et al., 2016). Of note, a method has recently been
developed to mature hiPSC-CMs sufficiently to harvest isolated
myofibrils for mechanics measurements to determine how
sarcomeric mutations directly affect the organelle in which they
are located (Pioner et al., 2016).
With the addition of this assay, it is now possible
to characterize the functional properties of hiPSC-CMs on
subcellular, cellular, and multicellular levels, a crucial set of
tools for cardiomyopathy disease modeling. Studying the effects
of disease-associated mutations at each level of organization
provides insight into distinct aspects of cardiomyocyte function
and how they are affected by the mutation of interest. Myofibril
mechanics measurements assess the contractile ability of the
hiPSC-CMs independent of the influences of the cell’s Ca2+
handling properties or intracellular signaling pathways. Single
cell measurements assess the function of myofibrils in the context
of whole-cell function, but without the influence of cell-cell
communication. Finally, multicellular tissue constructs provide
insight into the effects of cellular junctions and environmental
cues from extracellular matrix, and is currently the most
physiological setting in which to study hiPSC-CMs in vitro. By
performing these multiscale analyses in an in vitro setting, where
the internal and external environments can be manipulated,
it is now possible to study how molecular level changes in
myofilament protein structure and function (with mutations)
affect contractile fibrils and how this may influence coupled
systems such as the calcium handling, energetic production, and
protein expression systems in cells and tissue. In turn this should
provide new insight into which levels of structural organization
are most affected during the initiation and propagation of disease
phenotype, and whether the disease phenotype requires neuro-
humeral input.
A blessing and a curse central to the use of hiPSC-CMs
as models for familial cardiomyopathies is the maturity of the
cells. By most electrophysiological, morphological, metabolic,
and mechanical measures, these cells are far from an adult
phenotype (Yang et al., 2014). Although it can be difficult to
match hiPSC-CMs to an exact gestational age in vivo, a recent
study suggests when cells are matured on nanopatterned surfaces
for out to 80–100 days in culture they have adult-like cell size and
morphological characteristics. These cells express the adult form
of cardiac myosin (β-myosin from MYH7), although isoform
studies of troponin I suggest a fetal stage of expression (Bedada
et al., 2014). Additionally, their myofibril mechanical properties
and sarcomere ultrastructure match those of myofibrils from 75
day fetal heart tissue (Pioner et al., 2016). Thus, caution should
be used in judging the developmental state of these hiPSC-CMs,
based on appearance at the light microscope level.
Phenotyping cells at such an immature state is also a double-
edged sword for studying genetic cardiomyopathies (summarized
in Table 1). Many genetic cardiomyopathies clinically present
in adulthood, and there are concerns about whether in vitro
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TABLE 1 | A summary of the benefits and drawbacks of using hiPSC-CMs to study familial cardiomyopathies.
Pros Cons
Moderate throughput for studying different mutations using CRISPR/Cas9 Lack of neuro-hormonal, endocrine, and paracrine responses
Able to study mutations that would be lethal in vivo Immaturity of protein expression, ultrastructure, morphology, mechanical
properties
Provides insight during development of disease to understand mechanisms
Using isogenic controls allows for rigorous tests of causality and comparisons of mutations
modeling will demonstrate an appropriate disease phenotype
that recapitulates what occurs in vivo. However, in these
familial-based diseases there are likely changes occurring in the
myocardium well before many cardiomyopathies are detected
clinically that can be identified using in vitro assays. For example,
a recent study using hiPSC-CMs to study titin truncating
mutations as a basis for dilated cardiomyopathy noted a disease
phenotype in several assay systems, despite the fact that DCM
associated with these mutations is usually detected well into
adulthood (Hinson et al., 2015).
In fact, the immaturity of hiPSC-CMs can be beneficial
for studying genetic cardiomyopathies. Studies that utilize
animal models of cardiomyopathy often focus on characterizing
end-stage phenotypes, contributing data mostly to enhance
understanding of the final presentation of the disease.
Alternatively, the fetal-like properties of hiPSC-CMs can
provide mechanistic insight into early differences in function
and structure present in cardiomyopathy that may be difficult
or impossible to tease out in an in vivo system. For mutations
in proteins that are not expressed initially in cardiomyocyte
differentiation, but later in the timeline of development, it
should be possible to determine the seminal event that leads to
disease development and associated compensatory mechanisms.
This developmental view of disease progression is particularly
important as genetic testing grows in prevalence and robustness,
and the possibility of pre-emptively treating genetic diseases
before they present clinically becomes more likely. Using hiPSC-
CMs as a model of genetic cardiomyopathies can allow for these
crucial studies to understand how they develop, so that the
progression or development of them can be prevented.
Looking forward, additional new tools are being developed
that, combined with current technology, will allow for more
and better models of disease in a dish. One example of this is
the development of hiPSC lines that express proteins from the
endogenous loci with a linked fluoro-tag that allow for studies
of structural development with repeated live cell imaging (Ding
et al., 2013). Another tool is optogenetics, which has been used
primarily by neuroscientists to date (Steinbeck et al., 2015). The
ability to express channels that can provide temporal and spatial
control of stimulation or inhibition of depolarization could be
quite useful for developing culture-based models of arrhythmia-
genesis and long Q-T syndrome, but may also provide insight to
how sarcomere protein mutations disrupt the balance between
the contractile apparatus and Ca2+ cycling dynamics.
There still remain many limitations of in vitro models and
some aspects of disease will be challenging or impossible to study
using hiPSC-CMs. Examples include the complex temporal and
spatial influence of neuro-hormonal, paracrine, and endocrine
factors and how these are influenced by the structural and
functional changes resulting frommutant protein expression. On
the other hand, these new and emerging approaches will allow
for studies that are impossible to perform with other platforms
(e.g., early development, studyingmutations that would be lethal)
and inform on design of animal models that can probe those
aspects. Ultimately these tools will be most useful when used in
conjunction with in vivomodels.
In summary, a new generation of biophysical, gene editing,
and bioengineering approaches that are emerging holds great
promise and potential as tools to improve our understanding of
cardiac muscle development and the initiation and early-stage
progression of disease development. These, in turn, will allow for
better models used for drug and small molecule screening and the
next generation of targeted therapies for heart failure.
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